Antibodies to plasmodium falciparum erythrocyte-binding antigen-175 are associated with protection from clinical malaria

Matthew B. McCarra, George Ayodo, Peter O. Sumba, James W. Kazura, Ann M. Moormann, David L. Narum, Chandy John

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: Antibodies to blood-stage Plasmodium falciparum antigens have been associated with protection against clinical malaria in some studies but not others. Many of these studies have not assessed whether high-titer antibodies are associated with protection and have not adjusted for differences in malaria exposure. Methods: The presence of high-titer antibodies to apical membrane antigen-1, erythrocyte-binding antigen-175 (EBA-175), and merozoite surface protein-119 (MSP-119) was assessed in 87 children living in a malaria holoendemic area of Kenya. The children were prospectively assessed during 1 year for clinical malaria. Results: In unadjusted analyses, high-titer antibodies to MSP-119, but not EBA-175 or apical membrane antigen-1, were associated with protection from clinical malaria. However, after adjustment for exposure, only high-titer antibodies to EBA-175 were associated with protection from clinical malaria (hazard ratio, 0.48; 95% confidence interval [CI], 0.24, 0.95; P = 0.03), and with reduced episodes of clinical malaria (incidence rate ratio, 0.50; 95% CI, 0.31, 0.81; P = 0.005). A trend toward increased protection from clinical malaria in children was seen with antibodies to both EBA-175 and MSP-119 (hazard ratio, 0.26; 95% CI, 0.03, 1.94; P = 0.18). CONCLUSIONS:: High-titer antibodies to EBA-175 are associated with protection from clinical malaria in children in a malaria holoendemic area of Kenya. Accurate estimates of antibody-associated protection from clinical malaria require adjustment for malaria exposure.

Original languageEnglish (US)
Pages (from-to)1037-1042
Number of pages6
JournalPediatric Infectious Disease Journal
Volume30
Issue number12
DOIs
StatePublished - Dec 2011
Externally publishedYes

Fingerprint

Plasmodium falciparum
Malaria
Antibodies
Antigens
Merozoites
Erythrocytes
Membrane Proteins
Kenya
Confidence Intervals
Plasmodium erythrocyte-binding antigen 175
Membranes

Keywords

  • children
  • EBA-175
  • holoendemic
  • malaria

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Infectious Diseases
  • Microbiology (medical)

Cite this

Antibodies to plasmodium falciparum erythrocyte-binding antigen-175 are associated with protection from clinical malaria. / McCarra, Matthew B.; Ayodo, George; Sumba, Peter O.; Kazura, James W.; Moormann, Ann M.; Narum, David L.; John, Chandy.

In: Pediatric Infectious Disease Journal, Vol. 30, No. 12, 12.2011, p. 1037-1042.

Research output: Contribution to journalArticle

McCarra, Matthew B. ; Ayodo, George ; Sumba, Peter O. ; Kazura, James W. ; Moormann, Ann M. ; Narum, David L. ; John, Chandy. / Antibodies to plasmodium falciparum erythrocyte-binding antigen-175 are associated with protection from clinical malaria. In: Pediatric Infectious Disease Journal. 2011 ; Vol. 30, No. 12. pp. 1037-1042.
@article{716beacb3fdf45e7b375ddb534f93124,
title = "Antibodies to plasmodium falciparum erythrocyte-binding antigen-175 are associated with protection from clinical malaria",
abstract = "Background: Antibodies to blood-stage Plasmodium falciparum antigens have been associated with protection against clinical malaria in some studies but not others. Many of these studies have not assessed whether high-titer antibodies are associated with protection and have not adjusted for differences in malaria exposure. Methods: The presence of high-titer antibodies to apical membrane antigen-1, erythrocyte-binding antigen-175 (EBA-175), and merozoite surface protein-119 (MSP-119) was assessed in 87 children living in a malaria holoendemic area of Kenya. The children were prospectively assessed during 1 year for clinical malaria. Results: In unadjusted analyses, high-titer antibodies to MSP-119, but not EBA-175 or apical membrane antigen-1, were associated with protection from clinical malaria. However, after adjustment for exposure, only high-titer antibodies to EBA-175 were associated with protection from clinical malaria (hazard ratio, 0.48; 95{\%} confidence interval [CI], 0.24, 0.95; P = 0.03), and with reduced episodes of clinical malaria (incidence rate ratio, 0.50; 95{\%} CI, 0.31, 0.81; P = 0.005). A trend toward increased protection from clinical malaria in children was seen with antibodies to both EBA-175 and MSP-119 (hazard ratio, 0.26; 95{\%} CI, 0.03, 1.94; P = 0.18). CONCLUSIONS:: High-titer antibodies to EBA-175 are associated with protection from clinical malaria in children in a malaria holoendemic area of Kenya. Accurate estimates of antibody-associated protection from clinical malaria require adjustment for malaria exposure.",
keywords = "children, EBA-175, holoendemic, malaria",
author = "McCarra, {Matthew B.} and George Ayodo and Sumba, {Peter O.} and Kazura, {James W.} and Moormann, {Ann M.} and Narum, {David L.} and Chandy John",
year = "2011",
month = "12",
doi = "10.1097/INF.0b013e31822d1451",
language = "English (US)",
volume = "30",
pages = "1037--1042",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Antibodies to plasmodium falciparum erythrocyte-binding antigen-175 are associated with protection from clinical malaria

AU - McCarra, Matthew B.

AU - Ayodo, George

AU - Sumba, Peter O.

AU - Kazura, James W.

AU - Moormann, Ann M.

AU - Narum, David L.

AU - John, Chandy

PY - 2011/12

Y1 - 2011/12

N2 - Background: Antibodies to blood-stage Plasmodium falciparum antigens have been associated with protection against clinical malaria in some studies but not others. Many of these studies have not assessed whether high-titer antibodies are associated with protection and have not adjusted for differences in malaria exposure. Methods: The presence of high-titer antibodies to apical membrane antigen-1, erythrocyte-binding antigen-175 (EBA-175), and merozoite surface protein-119 (MSP-119) was assessed in 87 children living in a malaria holoendemic area of Kenya. The children were prospectively assessed during 1 year for clinical malaria. Results: In unadjusted analyses, high-titer antibodies to MSP-119, but not EBA-175 or apical membrane antigen-1, were associated with protection from clinical malaria. However, after adjustment for exposure, only high-titer antibodies to EBA-175 were associated with protection from clinical malaria (hazard ratio, 0.48; 95% confidence interval [CI], 0.24, 0.95; P = 0.03), and with reduced episodes of clinical malaria (incidence rate ratio, 0.50; 95% CI, 0.31, 0.81; P = 0.005). A trend toward increased protection from clinical malaria in children was seen with antibodies to both EBA-175 and MSP-119 (hazard ratio, 0.26; 95% CI, 0.03, 1.94; P = 0.18). CONCLUSIONS:: High-titer antibodies to EBA-175 are associated with protection from clinical malaria in children in a malaria holoendemic area of Kenya. Accurate estimates of antibody-associated protection from clinical malaria require adjustment for malaria exposure.

AB - Background: Antibodies to blood-stage Plasmodium falciparum antigens have been associated with protection against clinical malaria in some studies but not others. Many of these studies have not assessed whether high-titer antibodies are associated with protection and have not adjusted for differences in malaria exposure. Methods: The presence of high-titer antibodies to apical membrane antigen-1, erythrocyte-binding antigen-175 (EBA-175), and merozoite surface protein-119 (MSP-119) was assessed in 87 children living in a malaria holoendemic area of Kenya. The children were prospectively assessed during 1 year for clinical malaria. Results: In unadjusted analyses, high-titer antibodies to MSP-119, but not EBA-175 or apical membrane antigen-1, were associated with protection from clinical malaria. However, after adjustment for exposure, only high-titer antibodies to EBA-175 were associated with protection from clinical malaria (hazard ratio, 0.48; 95% confidence interval [CI], 0.24, 0.95; P = 0.03), and with reduced episodes of clinical malaria (incidence rate ratio, 0.50; 95% CI, 0.31, 0.81; P = 0.005). A trend toward increased protection from clinical malaria in children was seen with antibodies to both EBA-175 and MSP-119 (hazard ratio, 0.26; 95% CI, 0.03, 1.94; P = 0.18). CONCLUSIONS:: High-titer antibodies to EBA-175 are associated with protection from clinical malaria in children in a malaria holoendemic area of Kenya. Accurate estimates of antibody-associated protection from clinical malaria require adjustment for malaria exposure.

KW - children

KW - EBA-175

KW - holoendemic

KW - malaria

UR - http://www.scopus.com/inward/record.url?scp=81855175965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81855175965&partnerID=8YFLogxK

U2 - 10.1097/INF.0b013e31822d1451

DO - 10.1097/INF.0b013e31822d1451

M3 - Article

VL - 30

SP - 1037

EP - 1042

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

IS - 12

ER -